WuXi Clinical Development Services Expands Use of Medidata’s Cloud Technology Platform
April 24 2017 - 5:30PM
Business Wire
Leading Global Pharmaceutical,
Biopharmaceutical and Medical Device Open-access Capability and
Technology Platform Company Adopts Medidata’s Cloud-based Study
Conduct Solutions
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based solutions for clinical research in life sciences, today
announced an expanded partnership with WuXi Clinical Development
Services (“WuXi CDS”), a wholly-owned subsidiary of the global
pharmaceutical, biopharmaceutical and medical device open-access
capability and technology platform company, WuXi AppTec.
WuXi CDS is standardizing on the Medidata Clinical Cloud® to
enhance its capabilities in early-phase and bioequivalence (BE)
studies, bringing operational efficiencies to its customers’
clinical development programs across the country.
“WuXi CDS’ strengthened partnership with Medidata reinforces our
commitment to advancing the scientific goals of our customers—both
big and small, global and local,” said Mr. Jinjin Liang, Vice
President, Head of WuXi Clinical Development Services. “Medidata’s
agile, globally-validated platform is enabling our study teams to
conduct insightful and value-driven clinical research in a timely
manner—ultimately helping us serve the needs of our clients to
bring innovative, breakthrough products to the Chinese market.
We’re excited about taking our R&D programs to the next level,
and look forward to entering a long-term strategic relationship
with Medidata.”
WuXi CDS offers comprehensive Phase I–IV clinical development
services for pharmaceutical, biologic and medical devices companies
in China and abroad. In increasing its adoption of Medidata Rave®,
the industry’s leading cloud-based technology for electronic data
capture (EDC), management and reporting, WuXi will provide more
flexible, customized strategic solutions to advance the development
of new therapies across a number of therapeutic areas, including:
oncology, immunology, infectious diseases, respiratory,
gastroenterology, hematology, cardio-metabolic, dermatology and
gynecology. WuXi has also recently become accredited in Medidata’s
randomization and trial supply management solution (Medidata
Balance®), which it is leveraging on an increasing number of
domestic studies.
“We are thrilled to be working with WuXi CDS, a company that is
uniquely positioned to bring highly specialized clinical expertise
and deep local knowledge to both the global and Chinese market,”
said Edwin Ng, Medidata’s vice president of field operations, APeJ
(Asia Pacific except Japan). “At Medidata, we share WuXi CDS’
vision of conducting high quality clinical research, and we’re
proud that our robust, cutting-edge technology is playing a key
role in supporting the organization’s strong portfolio of clinical
studies for today’s most prevalent illnesses.”
Mike Capone, Medidata’s chief operating officer, added:
“Medidata is proudly working with more than 100 CROs, as well as
services, consulting and technical partners, to help sponsors
realize the value and powerful new insights that technology and
data analytics can bring to their clinical trials. WuXi is a market
leader and a strong agent of change for the global life sciences
industry, and we’re committed to further supporting the team’s
efforts to accelerate promising new drug compounds, biologics and
medical devices for its clients and their patients everywhere.”
Connect with Medidata
- Read our blog, Geeks Talk
Clinical
- Tweet this: .@WuXi_AppTec
#ClinicalDevelopment Services selects #MedidataRave for streamlined
#datacapture & study ops http://ow.ly/DEOj30b7WHZ
@Medidata
- Follow us on
Twitter: @Medidata
- Find us on LinkedIn
About WuXi Clinical Development Services
WuXi Clinical Development Services is a wholly-owned subsidiary
of WuXi AppTec in China. The company offers comprehensive Phase I –
IV clinical development services for pharmaceuticals, biologics,
and medical devices. WuXi CDS specializes in helping bring
innovative, breakthrough products to market – a process that
demands stringent quality control and experienced professionals
from Phase I through to final submission.
WuXi CDS also offers flexible, customized strategic solutions –
professionals who deliver services right from the clients’ offices,
supporting specific tasks or helping ride out the peaks and troughs
inherent in clinical development project timelines.
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
nearly 850 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 17 of the world's
top 25 global pharmaceutical companies and is used by 16 of the top
20 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170424006578/en/
Medidata SolutionsInvestors:Anthony D’Amico,
+1-732-767-4331adamico@mdsol.comorMedia – U.S. &
EMEA:Dick Wolfe, +1-646-483-2988dwolfe@mdsol.comorMedia –
APeJ:Da Jeong Chong, +82 2-2015-7715dchong@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024